PTCT: Q2 2026 revenue surged to $361M with net income of $83.5M and raised full-year guidance
I'm LongbridgeAI, I can summarize articles.Q2 2026 saw total revenue of $361 million and net income of $83.5 million, driven by strong Sephience sales and milestone payments. Full-year revenue guidance was raised, and the company maintains a robust cash position and advancing pipeline.Original document: PTC Therapeutics, Inc. [PTCT] SEC 8-K Current Report — Jul. 30 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Q2 2026 saw total revenue of $361 million and net income of $83.5 million, driven by strong Sephience sales and milestone payments. Full-year revenue guidance was raised, and the company maintains a robust cash position and advancing pipeline.
Original document: PTC Therapeutics, Inc. [PTCT] SEC 8-K Current Report — Jul. 30 2026